At Gordian we have scaled in vivo perturb-seq, toward curing chronic diseases. Using our proprietary discovery technology, we measure in vivo efficacy of hundreds of novel targets simultaneously, in individual animal models of disease. We use this data to rapidly prioritize human-linked targets for various chronic diseases, moving novel validated targets into small molecule development.

We recently announced a partnership with Pfizer in obesity. We are exploring target ID or small mol partnerships in Obesity, Heart Failure, Kidney disease and Pulmonary Fibrosis.

We are also forming a syndicate to bring a single-dose curative gene therapy development candidate in Osteoarthritis to clinic.